Partner to

Let’s partner to transform medicine—
and succeed together

At Assembly Bio, we take pride in the ingenuity, agility and rigor we apply to the scientific research we do. As a result, we’ve built some of the most cutting-edge drug discovery platforms in biopharma today. Our R&D effort is strong. It can be even stronger with the right academic and corporate partnerships in place.

Assembly Bio has a license and collaboration agreement with BeiGene to develop and commercialize our HBV product candidates vebicorvir (VBR, ABI-H0731), and ABI-H3733 in China, including Hong Kong, Macau and Taiwan.

Assembly Bio and Arbutus Biopharma have a clinical collaboration agreement to evaluate a triple combination treatment with Assembly Bio’s lead HBV core inhibitor VBR in combination with Arbutus’ proprietary GalNAc delivered RNAi compound AB-729 and standard-of-care therapy for the treatment of patients with chronic HBV infection.1

1While Assembly Bio has discontinued further development of first-generation core inhibitor, vebicorvir (VBR), a Phase 2 triple combination study conducted in collaboration with Arbutus Biopharma evaluating VBR + NrtI + Arbutus’ investigational RNAi is ongoing.

If your organization is interested in collaborating with Assembly Bio
on a potential research and development venture, please
contact us at: BD@assemblybio.com.